Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price rose 1.1% during trading on Monday . The stock traded as high as $26.40 and last traded at $26.29. Approximately 8,836,862 shares were traded during trading, a decline of 79% from the average daily volume of 41,983,879 shares. The stock had previously closed at $26.00.
Analysts Set New Price Targets
A number of research firms recently issued reports on PFE. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. TD Cowen downgraded shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus target price of $36.33.
Get Our Latest Report on PFE
Pfizer Stock Up 1.0 %
The company's 50 day moving average price is $27.11 and its two-hundred day moving average price is $28.62. The firm has a market cap of $148.70 billion, a PE ratio of 73.36, a PEG ratio of 1.17 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company's revenue was down 41.3% on a year-over-year basis. During the same period last year, the firm earned $1.14 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.
Institutional Trading of Pfizer
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Pfizer in the 4th quarter worth $2,129,927,000. Wellington Management Group LLP raised its holdings in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company's stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company's stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company's stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Pfizer by 30.9% in the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company's stock valued at $797,901,000 after purchasing an additional 5,678,004 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
